Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2024-205455

Published: 2024

Journal Articles

DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia

Sanne Massaar, Emma Boertjes, Annelieke Zeilemaker, Jolinda Konijnenburg, Francois Kavelaars, Melissa Rijken, Tim Grob, Jurjen Versluis, Bob Lowenberg, Peter J. M. Valk, Mathijs Arnoud Sanders

Blood (2024) 144 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2024-209821

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Blood (2023) 142 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2023-182831

Published: 2023

Journal Articles

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A. Von Dem Borne, Emma Nicholson, Didier Blaise, Stephen Robinson, Jr., Aleksandr Kulagin, Sr., Claude-Éric Bulabois, Montserrat Rovira, Patrice Chevallier, Édouard Forcade, Jenny Louise Byrne, Jaime Sanz Caballer, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2023-186293

Published: 2023

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT

Thomas Heinicke, Myriam Labopin, Didier Blaise, Jaime Sanz, Ibrahim Yakoub-Agha, Thomas Cluzeau, Marco Ladetto, Jürgen Finke, Eric Deconinck, Jurjen Versluis, Urpu Salmenniemi, Andreas Neubauer, Eolia Brissot, Ali Bazarbachi, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4976.

https://doi.org/10.1182/blood-2023-174233

Published: 2023

Journal Articles

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 660.

https://doi.org/10.1182/blood-2023-185557

Published: 2023

Journal Articles

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, Maria Pilar Gallego Hernanz, Matthias Eder, Peter A. Von Dem Borne, Gerard Socié, Patrice Chevallier, Edouard Forcade, Andreas Neubauer, Frederic Baron, Ali Bazarbachi, Gesine Bug, Arnon Nagler, Christoph Schmid, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2023-182834

Published: 2023

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Nour Moukalled, Myriam Labopin, Jurjen Versluis, Gerard Socié, Didier Blaise, Urpu Salmenniemi, Alessandro Rambaldi, Tobias Gedde-Dahl, Eleni Tholouli, Nicolaus Kröger, Jean-Henri Bourhis, Peter A. Von Dem Borne, Etienne Daguindau, Édouard Forcade, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2023-185434

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2023-187095

Published: 2023

Journal Articles

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Blood (2022) 140 (Supplement 1): 8890–8892.

https://doi.org/10.1182/blood-2022-163055

Published: 2022

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2389–2391.

https://doi.org/10.1182/blood-2022-157890

Published: 2022

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Péter Reményi, Edouard Forcade, Nicolaus Kröger, Gerard Socie, Charles Craddock, Jean-Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean Elcheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4897–4898.

https://doi.org/10.1182/blood-2022-165069

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

NARROW

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT

Comparative Study for Haplo, MSD and MUD Allo-Hcts for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only